title: [Detection of soluble interleukin-2 receptor in the serum of patients with non-Hodgkin's lymphoma].
abstract: BACKGROUND
  Patients with non-Hodgkin's lymphoma (NHL) have increased serum levels of soluble interleukin-2 receptor (sCD25). In this study the authors investigate: a) the value of sCD25, compared to other serum markers, as tumor marker, and b) the relationship of the sCD25 with the response to therapy and prognosis.
  
  
  METHODS
  Serum interleukin-2 receptor (sCD25) levels were measured at diagnosis in 63 patients with NHL (low-grade lymphoma 30 and high-grade lymphoma 33).
  
  
  RESULTS
  High levels of sCD25 were found in these patients compared to a control group (median 1,757 U/ml vs 385 U/ml; p < 0.0001). Significant differences were also found between the high-grade group and the low-grade group, as a whole and within the same Ann Arbor stage. sCD25 showed a correlation coefficient higher than other serum parameters (albumin, LDH, beta 2-microglobulin, uric acid, C-reactive protein) with Ann Arbor stage and with the number of involved lymph nodes or extralymphatic organs. In the high-grade NHL, the median of sCD25 (3,000 U/ml) separates patients with differences in the overall survival (p = 0.0138) and in percentage of complete remisions (p = 0.0079). All the patients with sCD25 < or = 3,000 U/ml reached the remision. The association sCD25 > 3,000 U/ml and albumin < 3.5 g/dl selected to 5 out of 6 patients who failed induction chemotherapy, and only 2 out of 22 who reached the remision.
  
  
  CONCLUSIONS
  The sCD25 is the best serum factor for estimating tumor burden in NHL. sCD25 level isolates or associated with albumin provides prognostic information.
authors.affiliation: Servicio de Hematología y Hemoterapia, Hospital General de Galicia, Santiago de Compostela.
authors.forename: M
authors.initials: M
authors.lastname: Pérez Encinas
authors.forename: J L
authors.initials: JL
authors.lastname: Bello
authors.forename: A
authors.initials: A
authors.lastname: Bendaña
authors.forename: M J
authors.initials: MJ
authors.lastname: Rabuñal
authors.forename: S
authors.initials: S
authors.lastname: González
authors.forename: I
authors.initials: I
authors.lastname: Abuín
authors.forename: M
authors.initials: M
authors.lastname: Noya
authors.forename: C
authors.initials: C
authors.lastname: Cadarso
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor; D002097:C-Reactive Protein / Q000032:analysis; D003627:Data Interpretation, Statistical; D005260:Female; D006801:Humans; D007770:L-Lactate Dehydrogenase / Q000097:blood; D008228:Lymphoma, Non-Hodgkin / Q000097:blood* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D015375:Receptors, Interleukin-2 / Q000097:blood*; D012709:Serum Albumin / Q000032:analysis; D012995:Solubility; D013997:Time Factors; D014527:Uric Acid / Q000097:blood; D001613:beta 2-Microglobulin / Q000032:analysis
chemical_list: D014408:Biomarkers, Tumor; D015375:Receptors, Interleukin-2; D012709:Serum Albumin; D001613:beta 2-Microglobulin; D014527:Uric Acid; D002097:C-Reactive Protein; D007770:L-Lactate Dehydrogenase